Current treatment of inflammatory bowel disease in children

被引：11
作者：
Markowitz, J. [1 ]
机构：
[1] Schneider Childrens Hosp, NYU Sch Med, Div Pediat Gastroenterol, N Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY 11042 USA
来源：
DIGESTIVE AND LIVER DISEASE | 2008年 / 40卷 / 01期
关键词：
5-ASA; biologic therapy; children; corticosteroids; IBD; immunomodulators; nutritional therapy;
D O I：
10.1016/j.dld.2007.07.167
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Children with inflammatory bowel disease present formidable therapeutic challenges. As both Crohn's disease and ulcerative colitis remain medically incurable conditions associated with potentially significant morbidity, the focus of treatment must be to reduce or eliminate symptoms, optimize nutritional status, promote normal growth and development, prevent complications and minimize the potential psychological effects of these chronic illnesses. This review focuses on the evidence supporting the treatments currently used in children with inflammatory bowel disease, and suggests potential treatment algorithms for particular clinical circumstances. (c) 2007 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：16 / 21
页数：6
相关论文
共 34 条
  • [1] Methotrexate for induction of remission in refractory Crohn's disease
    Alfadhli, AAF
    McDonald, JWD
    Feagan, BG
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01):
  • [2] Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab
    Barrie, Arthur
    Plevy, Scott
    [J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2006, 35 (04) : 883 - +
  • [3] Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease
    Borrelli, O
    Bascietto, C
    Viola, F
    de Mesquita, MB
    Barbato, M
    Mancini, V
    Bosco, S
    Cucchiara, S
    [J]. DIGESTIVE AND LIVER DISEASE, 2004, 36 (05) : 342 - 347
  • [4] Oral tacrolimus treatment of severe colitis in children
    Bousvaros, A
    Kirschner, BS
    Werlin, SL
    Parker-Hartigan, L
    Daum, F
    Freeman, KB
    Balint, JP
    Day, AS
    Griffiths, AM
    Zurakowski, D
    Ferry, GD
    Leichtner, AM
    [J]. JOURNAL OF PEDIATRICS, 2000, 137 (06) : 794 - 799
  • [5] Toxicity of infliximab in the course of treatment of Crohn's disease
    Bratcher, JM
    Korelitz, BI
    [J]. EXPERT OPINION ON DRUG SAFETY, 2006, 5 (01) : 9 - 16
  • [6] Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
    Corken Mackey, Ann
    Green, Lanh
    Liang, Li-ching
    Dinndorf, Patricia
    Avigan, Mark
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 44 (02) : 265 - 267
  • [7] Review article: thiopurines in inflammatory bowel disease
    Derijks, L. J. J.
    Gilissen, L. P. L.
    Hooymans, P. M.
    Hommes, D. W.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (05) : 715 - 729
  • [8] Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence
    Desreumaux, P.
    Ghosh, S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 : 2 - 9
  • [9] Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
    Dubinsky, MC
    Lamothe, S
    Yang, HY
    Targan, SR
    Sinnett, D
    Théorêt, Y
    Seidman, EG
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : 705 - 713
  • [10] Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial
    Escher, JC
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (01) : 47 - 54
1234